Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NICODERM CQ

« Back to Dashboard

Nicoderm Cq is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NICODERM CQ is nicotine. There are twenty-eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the nicotine profile page.

Summary for Tradename: NICODERM CQ

Patents:2
Applicants:1
NDAs:1
Suppliers: see list5

Clinical Trials for: NICODERM CQ

Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge
Status: Completed Condition: Nicotine Pharmacokinetic Study

Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product
Status: Completed Condition: Tobacco Dependence

Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations
Status: Completed Condition: Smoking Cessation

Neural Mechanisms Underlying Nicotine and Alcohol Combinations
Status: Recruiting Condition: Focus: Effects of Nicotine and Alcohol on Brain Circuits

Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product.
Status: Completed Condition: Tobacco Dependence

Nicotine Vaccination and Nicotinic Receptor Occupancy
Status: Completed Condition: Nicotine Dependence

Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging
Status: Recruiting Condition: Nicotine Dependence

Bioequivalence Between an Oral Nicotine Replacement Product and NicoretteĀ® Gum
Status: Completed Condition: Tobacco Dependence

Nicotine Lozenge Bioequivalence Study
Status: Completed Condition: Smoking Cessation

Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
Status: Not yet recruiting Condition: Tobacco Dependence

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
NICODERM CQ
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020165Aug 2, 1996OTCYes8,075,911<disabled>Y<disabled>
Sanofi Aventis Us
NICODERM CQ
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020165Aug 2, 1996OTCYes8,663,680<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NICODERM CQ

Drugname Dosage Strength RLD Submissiondate
nicotineTransdermal System7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrsNicoderm CQ5/30/2014
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc